SU1648248A3 - Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола - Google Patents

Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола Download PDF

Info

Publication number
SU1648248A3
SU1648248A3 SU884356076A SU4356076A SU1648248A3 SU 1648248 A3 SU1648248 A3 SU 1648248A3 SU 884356076 A SU884356076 A SU 884356076A SU 4356076 A SU4356076 A SU 4356076A SU 1648248 A3 SU1648248 A3 SU 1648248A3
Authority
SU
USSR - Soviet Union
Prior art keywords
enantiomers
receptors
mixture
enantiomer
separation
Prior art date
Application number
SU884356076A
Other languages
English (en)
Russian (ru)
Inventor
Йоханнес Карьялайнен Арто
Эйнари Виртанен Раимо
Юхани Саволайнен Эйно
Original Assignee
Фармос-Ихтюмя Ой (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10620775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SU1648248(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фармос-Ихтюмя Ой (Фирма) filed Critical Фармос-Ихтюмя Ой (Фирма)
Application granted granted Critical
Publication of SU1648248A3 publication Critical patent/SU1648248A3/ru
Priority to LV930435A priority Critical patent/LV5241A3/xx
Priority to LTRP761A priority patent/LT2214B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SU884356076A 1987-07-16 1988-06-28 Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола SU1648248A3 (ru)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LV930435A LV5241A3 (lv) 1987-07-16 1993-05-28 enantiomeru maisijuma sadalisanas metode 4-Ú1-(2,3-dimetilfenil)etil¾-1h-imidazola d- un l-
LTRP761A LT2214B (lt) 1987-07-16 1993-07-07 4-(1-(2,3-dimetilfenil) etil) -h-imadazolo d-ir 1-enantiomeru misinio atskyrimo budas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8716803A GB2206880B (en) 1987-07-16 1987-07-16 Optical isomers of an imidazole derivative

Publications (1)

Publication Number Publication Date
SU1648248A3 true SU1648248A3 (ru) 1991-05-07

Family

ID=10620775

Family Applications (1)

Application Number Title Priority Date Filing Date
SU884356076A SU1648248A3 (ru) 1987-07-16 1988-06-28 Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола

Country Status (29)

Country Link
US (1) US4910214A (enExample)
EP (1) EP0300652B1 (enExample)
JP (1) JPH0625138B2 (enExample)
KR (1) KR940007311B1 (enExample)
CN (1) CN1022323C (enExample)
AT (1) ATE71941T1 (enExample)
AU (1) AU600839B2 (enExample)
BG (1) BG60473B2 (enExample)
CA (1) CA1337659C (enExample)
CY (2) CY1787A (enExample)
DD (1) DD281807A5 (enExample)
DE (2) DE3867945D1 (enExample)
DK (1) DK165788C (enExample)
ES (1) ES2038757T3 (enExample)
FI (1) FI95375C (enExample)
GB (1) GB2206880B (enExample)
GR (1) GR3003878T3 (enExample)
HK (1) HK56094A (enExample)
HU (1) HU198693B (enExample)
IE (1) IE60456B1 (enExample)
IL (1) IL87076A0 (enExample)
LU (1) LU91010I2 (enExample)
NL (1) NL300117I2 (enExample)
NO (2) NO170579C (enExample)
NZ (1) NZ225362A (enExample)
PT (1) PT88013B (enExample)
SU (1) SU1648248A3 (enExample)
UA (1) UA5560A1 (enExample)
ZA (1) ZA885134B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743999C2 (ru) * 2016-07-22 2021-03-01 Юниверсите Де Руан Способ разделения солей баклофена

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
IN187238B (enExample) * 1995-06-30 2002-03-09 Astra Ab
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5866579A (en) 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
JP4741131B2 (ja) 1999-10-29 2011-08-03 オリオン コーポレーション 低血圧およびショックの治療または予防
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
KR101859486B1 (ko) * 2009-05-15 2018-06-28 레크로파마, 인코포레이티드 설하용 덱스메데토미딘 조성물과 그의 사용 방법
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术（上海）有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
KR102190009B1 (ko) 2011-12-11 2020-12-15 바우닥스 바이오, 인코포레이티드 비강내 덱스메데토미딘(dexmedetomidine) 조성물 및 그 사용방법
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ITMI20120311A1 (it) * 2012-02-29 2013-08-30 Edmond Pharma Srl Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
WO2014028610A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
PT2906213T (pt) * 2012-10-15 2018-02-19 Orion Corp Um método veterinário para aliviar a aversão ao rúido
BR112016006848A2 (pt) 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
TWI645866B (zh) 2013-10-07 2019-01-01 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
CN105175339B (zh) * 2015-10-09 2018-01-16 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN114671811A (zh) * 2022-04-14 2022-06-28 南京正科医药股份有限公司 一种右美托咪定拆分副产物的外消旋化回收方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
DE3531682A1 (de) * 1985-09-05 1987-03-12 Thomae Gmbh Dr K (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Грингатейн Дж. Хими аминокислот и пептидов. - Мир, 1965, с.64-66. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743999C2 (ru) * 2016-07-22 2021-03-01 Юниверсите Де Руан Способ разделения солей баклофена

Also Published As

Publication number Publication date
CA1337659C (en) 1995-11-28
GB8716803D0 (en) 1987-08-19
CN1030576A (zh) 1989-01-25
DK386288D0 (da) 1988-07-11
DE3867945D1 (de) 1992-03-05
NZ225362A (en) 1990-07-26
GB2206880B (en) 1991-04-24
NO883155D0 (no) 1988-07-15
DE10399005I2 (de) 2012-06-06
DE10399005I1 (de) 2003-06-05
DK165788B (da) 1993-01-18
PT88013B (pt) 1995-03-01
DD281807A5 (de) 1990-08-22
CY1787A (en) 1995-10-20
ATE71941T1 (de) 1992-02-15
UA5560A1 (uk) 1994-12-28
NO170579B (no) 1992-07-27
IL87076A0 (en) 1988-12-30
KR890002030A (ko) 1989-04-07
ZA885134B (en) 1989-04-26
CY2004006I2 (el) 2009-11-04
NO883155L (no) 1989-01-17
FI95375C (fi) 1996-01-25
ES2038757T3 (es) 1993-08-01
PT88013A (pt) 1989-06-30
CY2004006I1 (el) 2009-11-04
GB2206880A (en) 1989-01-18
NO2003004I2 (no) 2005-03-21
NL300117I1 (nl) 2003-05-01
NL300117I2 (nl) 2003-10-01
IE882174L (en) 1989-01-16
FI95375B (fi) 1995-10-13
EP0300652B1 (en) 1992-01-22
IE60456B1 (en) 1994-07-13
BG60473B2 (bg) 1995-04-28
AU600839B2 (en) 1990-08-23
EP0300652A1 (en) 1989-01-25
FI882819A0 (fi) 1988-06-14
US4910214A (en) 1990-03-20
HUT48218A (en) 1989-05-29
HK56094A (en) 1994-06-03
JPH0625138B2 (ja) 1994-04-06
DK386288A (da) 1989-01-17
DK165788C (da) 1993-06-14
NO170579C (no) 1992-11-04
FI882819L (fi) 1989-01-17
KR940007311B1 (ko) 1994-08-12
CN1022323C (zh) 1993-10-06
JPS6434968A (en) 1989-02-06
HU198693B (en) 1989-11-28
LU91010I2 (fr) 2003-06-19
AU1894188A (en) 1989-01-19
GR3003878T3 (enExample) 1993-03-16

Similar Documents

Publication Publication Date Title
SU1648248A3 (ru) Способ разделени смеси @ - и @ -энантиомеров 4-[1-(2,3-диметилфенил)этил]-1Н-имидазола
Doxey et al. Selectivity of blocking agents for pre-and postsynaptic alpha-adrenoceptors
CH616674A5 (enExample)
US6313172B1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
SU1598869A3 (ru) Способ получени транс-3,4-изомеров производных 4-(3-оксифенил)-пиперидина
FI67543B (fi) Foerfarande foer framstaellning av farmakologiskt aktiv 2-(2-(1,4-benzodioxanyl))-2-imidazolin
BR112013006320B1 (pt) Composto, composição farmacêutica e seu uso
US7335803B2 (en) Methods and compositions for modulating alpha adrenergic receptor activity
SK282653B6 (sk) Deriváty (R)-(-)-metylfenyloxazolidinónu, liečivá tieto látky obsahujúce a ich použitie
DE69520430T2 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
Judy et al. Effect of l-dopa on sympathetic nerve activity and blood pressure in the spontaneously hypertensive rat.
EP1140875A1 (de) Sulfonyloxazolamine als therapeutische wirkstoffe
CA3213395A1 (en) Compositions and methods for treating polycythemia
JP4761683B2 (ja) 置換５−オキソ−５，６，７，８−テトラヒドロ−４ｈ−１−ベンゾピランおよびベンゾチオピランならびにそのａｍｐａ増強剤としての使用
DE2034640C3 (de) l-p-(7-Trifluormethyl-4-chinolyl) -amino-benzoyl-piperazine, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Bluthochdruck
DE2733698A1 (de) 1-niederalkyl-4,5-dihydro-5-phenyl- 2-niederalkoxycarbonylaminoimidazole und deren im phenylrest substituierte derivate
US6083964A (en) Optical resolution of racemic aminoalkylpyridine anticonvulsants and (+) aminoalkylpyridine enantiomers as highly potent orally effective anticonvulsant drugs and excitatory amino acid antagonists
SU1299506A3 (ru) Способ получени фармацевтически приемлемых солей транс-4 @ -5 @ -пропил-4,4а,5,6,7,8,8а,9-октагидро- @ /и @ / пиразоло /3,4- @ / хинолина
JPS60123418A (ja) 血管拡張剤
JPH06510060A (ja) スピロ環式ベンゾピランイミダゾリン類
JPS62242673A (ja) てんかんおよび不安状態の予防および治療用２，４，６−トリス−第三ブチルアミノ−１，３，５−トリアジン